Gavilimomab

加维莫单抗

Report date: 2023/04/25 13:51:01

Base Information

Drug NameGavilimomab
Drug Alias NameMonoclonal antibody ABX-CBLMonoclonal antibody CBL-1ABX-CBLAnti-CD147 monoclonal antibody ABX-CBLCBL-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionImmunosuppressantsAnti-CD147
TargetsBasigin
Therapy Area/IndicationsRejection of renal transplantationGraft vs Host DiseasePsoriasis +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbgenix Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsRejection of renal transplantationGraft vs Host DiseasePsoriasis +[4

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank